A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

Inclusion Criteria:

- Males or females, between 18 and 65 years of age, inclusive

- Within body mass index (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m^2),
inclusive

- In good health, determined by no clinically significant findings from medical
history, 12-lead electrocardiograms (ECGs), and vital signs

- Females will be non-pregnant, non-lactating, and either postmenopausal (at least 1
year of non therapy induced amenorrhea), surgically sterile (absence of ovaries
and/or uterus) for at least 90 days, or agree to remain abstinent or use a highly
effective method of contraception for at least 24 weeks after the single dose of
study drug

- Males will either be sterile or agree to remain abstinent or use a highly effective
method of contraception for at least 24 weeks after the single dose of study drug.
Male participants will refrain from sperm donation from Check-in (Day -1) until 24
weeks following study drug administration

Exclusion Criteria:

- Participation in any other investigational study drug or biological agent trial
(including investigational vaccines) in which receipt of an investigational study
drug occurred within 30 days or 5 half-lives or receipt of a biologic agent occurred
within 90 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) and
during the entire study

- Any prior treatment with etrolizumab or other anti integrin agents (including
natalizumab, vedolizumab, and efalizumab)

- Any prior exposure to immunosuppressive agents (e.g., methotrexate, azathoprine,
mercaptopurine)

- Use of IV steroids within 30 days prior to Screening;

- Chronic nonsteroidal anti inflammatory drug (NSAID)

- Use of any prescription medications/products within 14 days prior to Check in (Day
-1)

- History of demyelinating disease

- Neurological conditions or diseases

- History of cancer

- History of alcoholism or drug addiction within 1 year prior to Check-in (Day -1)

- History of active or latent tuberculosis (TB), regardless of treatment history

- History of recurrent opportunistic infections, severe disseminated viral infections
(e.g., herpes), or any serious opportunistic infection within the last 6 months

- Positive for human immunodeficiency virus (HIV) antibody

- Any current or recent signs or symptoms of infection

- Inability to sense pain (e.g., peripheral neuropathy) and have a history of or have
been diagnosed with a chronic pain syndrome